Valuation: Laboratorios Richmond S.A.C.I.F.

Market Cap 11TCr 6.92Cr 6.18Cr 5.68Cr 5.16Cr 9.69Cr 655.55Cr 9.93Cr 68Cr 27Cr 346Cr 26Cr 25Cr 1.1TCr P/E 2024
6.08x
P/E 2025 51.6x
Enterprise Value 34TCr 22Cr 20Cr 18Cr 16Cr 31Cr 2.07TCr 31Cr 214.17Cr 86Cr 1.09TCr 82Cr 80Cr 3.46TCr EV / Sales 2024
3.04x
EV / Sales 2025 3.08x
Free-Float
17.54%
Yield 2024
1.5%
Yield 2025 -
06/08 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
11/05 Laboratorios Richmond S.A.C.I.F. announces Annual dividend, payable on May 15, 2026 CI
07/05 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
07/03 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
06/11 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
08/25/08 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
09/25/09 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
08/25/08 Laboratorios Richmond S.A.C.I.F. announces Annual dividend, payable on May 15, 2025 CI
08/25/08 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
06/24/06 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 CI
13/24/13 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 CI
07/24/07 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
11/24/11 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
1 day-0.38%
1 week+0.38%
Current month+1.53%
1 month-12.25%
3 months-14.52%
6 months-18.96%
Current year-32.91%
1 week 1,250
Extreme 1250
1,390
1 month 1,250
Extreme 1250
1,580
Current year 1,250
Extreme 1250
2,130
1 year 1,250
Extreme 1250
2,300
3 years 595.5
Extreme 595.5
2,300
5 years 215
Extreme 215
2,300
10 years 24.8
Extreme 24.8
2,300
Manager TitleAgeSince
President - -
General Counsel - 29/04/2025
Corporate Officer/Principal - 29/04/2025
Director TitleAgeSince
Director/Board Member - -
Director/Board Member - -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-0.38%+0.38%-16.93%+92.59% 6.96Cr
-0.11%+10.18%+63.34%+142.88% 1,25700Cr
-1.62%-0.05%+40.93%+77.16% 65TCr
-0.98%-0.26%+31.17%+99.64% 51TCr
-1.56%-1.39%+51.02%+64.18% 39TCr
-2.49%+2.89%+68.26%+40.66% 37TCr
-0.02%+3.15%+32.47%+55.33% 30TCr
-0.72%+7.05%+10.34%+32.79% 29TCr
-0.90%+3.74%+54.56%+73.02% 25TCr
-1.68%+5.53%+39.80%+106.17% 21TCr
Average -0.89%+3.74%+37.50%+78.44% 42.27TCr
Weighted average by Cap. -0.55%+5.30%+47.77%+91.67%

Financials

2024 2025
Net sales 9.18TCr 5.94Cr 5.3Cr 4.87Cr 4.43Cr 8.31Cr 562.41Cr 8.52Cr 58Cr 23Cr 296.84Cr 22Cr 22Cr 940.86Cr 13TCr 8.2Cr 7.32Cr 6.73Cr 6.11Cr 11Cr 776.43Cr 12Cr 80Cr 32Cr 409.8Cr 31Cr 30Cr 1.3TCr
Net income 2.38TCr 1.54Cr 1.38Cr 1.27Cr 1.15Cr 2.16Cr 146.1Cr 2.21Cr 15Cr 6.08Cr 77Cr 5.79Cr 5.67Cr 244.4Cr 308.78Cr 19.97L 17.84L 16.39L 14.89L 27.95L 19Cr 28.66L 1.96Cr 78.7L 9.99Cr 74.96L 73.36L 32Cr
Net Debt 13TCr 8.64Cr 7.72Cr 7.09Cr 6.44Cr 12Cr 818.84Cr 12Cr 85Cr 34Cr 432.18Cr 32Cr 32Cr 1.37TCr 23TCr 15Cr 13Cr 12Cr 11Cr 21Cr 1.42TCr 21Cr 146.38Cr 59Cr 747.12Cr 56Cr 55Cr 2.37TCr
Projected Income Statement - Annual - Laboratorios Richmond S.A.C.I.F.
Logo Laboratorios Richmond S.A.C.I.F.
Laboratorios Richmond SACIF is an Argentina-based company, which is engaged in the development and manufacture of pharmaceuticals. The Company's product categories include: Antiviral, under the brands Ciganclor, Lazinevir, Leuzan, Mivuten, Probirase, Protease, Selmivir, Trivenz, Virontar, Virontar N, Virontar 600, Vuclodir, Zepril, Zetavudin, and Zetrotax; Oncologi and Oncohematologic, under the brands Bemux, Capecit, Doxetal, Drifen, Espasevit, Fontrax, Gezt, and Monofer, among others; Cardiovascular, under the brands Amze 5, Amze 10, Antiplaq, Bilip 10, Bilip 20, Tacardia, and Timezol 20, among others; Neuropsychiatric, under the brands Dalam 15, Dolofrix 10, Donepes 5, and Prilben 10, among others, as well as Hospital, under the brands Amidiaz, Dalam, and Fentax, among others.
Employees
620
Date Price Change Volume
03/26/03 ARS 1,325.00 -0.38% 1,306
02/26/02 ARS 1,330.00 +1.92% 827
30/26/30 ARS 1,305.00 +0.38% 693
29/26/29 ARS 1,300.00 -5.80% 982
28/26/28 ARS 1,380.00 +6.98% 784
  1. Stock Market
  2. Stocks
  3. RICH Stock